Novo Nordisk (0QIU) Share Forecast & Price Target

Compare

72 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QIU Analyst Ratings

Moderate Buy

6 Buy

4 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QIU Stock 12 Month Forecast

Average Price Target

kr407.60

▲(31.34% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is kr407.60 with a high forecast of kr540.00 and a low forecast of kr290.00. The average price target represents a 31.34% change from the last price of kr310.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"289":"kr289","404":"kr404","519":"kr519","634":"kr634","749":"kr749"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":540,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr540.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":407.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr407.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr290.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[289,404,519,634,749],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,315.27,332.55692307692306,349.84384615384613,367.1307692307692,384.4176923076923,401.70461538461535,418.9915384615384,436.27846153846156,453.5653846153846,470.8523076923077,488.1392307692307,505.42615384615385,522.7130769230769,{"y":540,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,315.27,322.3723076923077,329.4746153846154,336.5769230769231,343.67923076923074,350.78153846153845,357.88384615384615,364.98615384615385,372.08846153846156,379.19076923076926,386.2930769230769,393.3953846153846,400.4976923076923,{"y":407.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,315.27,313.32615384615383,311.3823076923077,309.4384615384615,307.4946153846154,305.5507692307692,303.60692307692307,301.6630769230769,299.71923076923076,297.7753846153846,295.83153846153846,293.8876923076923,291.94384615384615,{"y":290,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":748.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":746.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":604.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":594.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":623.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":427.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr540.00

Average Price Targetkr407.60

Lowest Price Targetkr290.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kerry Holford

Berenberg Bank

kr425→kr400

Buy

28.89%

Upside

Reiterated

11/14/25

Berenberg Bank Keeps Their Buy Rating on Novo Nordisk (0QIU)

Matthew Weston

UBS

kr315

Hold

1.50%

Upside

Reiterated

11/10/25

UBS Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

11/10/25

DZ BANK AG Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Emmanuel Papadakis

Deutsche Bank

kr600→kr475

Buy

53.06%

Upside

Reiterated

11/10/25

Novo Nordisk (0QIU) Gets a Buy from Deutsche Bank

Sachin Jain

Bank of America Securities

kr375→kr315

Hold

1.50%

Upside

Reiterated

11/10/25

Bank of America Securities Keeps Their Hold Rating on Novo Nordisk (0QIU)

David Evans

Kepler Capital

kr510

Buy

64.34%

Upside

Reiterated

11/10/25

Kepler Capital Remains a Buy on Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

kr392→kr391

Buy

25.99%

Upside

Reiterated

11/06/25

Novo Nordisk (0QIU) Gets a Buy from Goldman Sachs

Richard Vosser

J.P. Morgan

kr500

Buy

61.11%

Upside

Reiterated

11/05/25

J.P. Morgan Sticks to Its Buy Rating for Novo Nordisk (0QIU)

Michael Leuchten

Jefferies

kr290

Sell

-6.55%

Downside

Reiterated

11/05/25

Jefferies Remains a Sell on Novo Nordisk (0QIU)

Florent Cespedes

Bernstein

kr540

Buy

74.00%

Upside

Reiterated

11/04/25

Bernstein Sticks to Its Buy Rating for Novo Nordisk (0QIU)

Nico Chen

DBS

kr340

Hold

9.56%

Upside

Upgraded

08/22/25

Novo Nordisk upgraded to Hold from Sell at DBS BankNovo Nordisk upgraded to Hold from Sell at DBS Bank

Emily Field

Barclays

kr375

Hold

20.84%

Upside

Reiterated

08/04/25

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

Martial Descoutures

Oddo BHF

kr465

Hold

49.84%

Upside

Downgraded

07/30/25

Novo Nordisk downgraded to Neutral from Outperform at Oddo BHFNovo Nordisk downgraded to Neutral from Outperform at Oddo BHF

Thibault Boutherin

Morgan Stanley

kr550

Hold

77.22%

Upside

Reiterated

06/23/25

Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Eric Le Berrigaud

Stifel Nicolaus

kr780→kr700

Hold

125.56%

Upside

Downgraded

03/03/25

Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kerry Holford

Berenberg Bank

kr425→kr400

Buy

28.89%

Upside

Reiterated

11/14/25

Berenberg Bank Keeps Their Buy Rating on Novo Nordisk (0QIU)

Matthew Weston

UBS

kr315

Hold

1.50%

Upside

Reiterated

11/10/25

UBS Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

11/10/25

DZ BANK AG Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Emmanuel Papadakis

Deutsche Bank

kr600→kr475

Buy

53.06%

Upside

Reiterated

11/10/25

Novo Nordisk (0QIU) Gets a Buy from Deutsche Bank

Sachin Jain

Bank of America Securities

kr375→kr315

Hold

1.50%

Upside

Reiterated

11/10/25

Bank of America Securities Keeps Their Hold Rating on Novo Nordisk (0QIU)

David Evans

Kepler Capital

kr510

Buy

64.34%

Upside

Reiterated

11/10/25

Kepler Capital Remains a Buy on Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

kr392→kr391

Buy

25.99%

Upside

Reiterated

11/06/25

Novo Nordisk (0QIU) Gets a Buy from Goldman Sachs

Richard Vosser

J.P. Morgan

kr500

Buy

61.11%

Upside

Reiterated

11/05/25

J.P. Morgan Sticks to Its Buy Rating for Novo Nordisk (0QIU)

Michael Leuchten

Jefferies

kr290

Sell

-6.55%

Downside

Reiterated

11/05/25

Jefferies Remains a Sell on Novo Nordisk (0QIU)

Florent Cespedes

Bernstein

kr540

Buy

74.00%

Upside

Reiterated

11/04/25

Bernstein Sticks to Its Buy Rating for Novo Nordisk (0QIU)

Nico Chen

DBS

kr340

Hold

9.56%

Upside

Upgraded

08/22/25

Novo Nordisk upgraded to Hold from Sell at DBS BankNovo Nordisk upgraded to Hold from Sell at DBS Bank

Emily Field

Barclays

kr375

Hold

20.84%

Upside

Reiterated

08/04/25

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

Martial Descoutures

Oddo BHF

kr465

Hold

49.84%

Upside

Downgraded

07/30/25

Novo Nordisk downgraded to Neutral from Outperform at Oddo BHFNovo Nordisk downgraded to Neutral from Outperform at Oddo BHF

Thibault Boutherin

Morgan Stanley

kr550

Hold

77.22%

Upside

Reiterated

06/23/25

Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Eric Le Berrigaud

Stifel Nicolaus

kr780→kr700

Hold

125.56%

Upside

Downgraded

03/03/25

Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

1 Month

xxx

Success Rate

39/63 ratings generated profit

Average Return

+1.17%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.90% of your transactions generating a profit, with an average return of +1.17% per trade.

3 Months

xxx

Success Rate

38/63 ratings generated profit

Average Return

+2.19%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.32% of your transactions generating a profit, with an average return of +2.19% per trade.

1 Year

Richard VosserJ.P. Morgan

Success Rate

43/63 ratings generated profit

Average Return

+14.71%

reiterated a buy rating 13 days ago

Copying Richard Vosser's trades and holding each position for 1 Year would result in 68.25% of your transactions generating a profit, with an average return of +14.71% per trade.

2 Years

xxx

Success Rate

15/22 ratings generated profit

Average Return

-8.59%

reiterated a xxx

rating 13 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.18% of your transactions generating a profit, with an average return of -8.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QIU Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QIU has received 29 Buy Ratings, 16 Hold Ratings, and 2 Sell Ratings. 0QIU average Analyst price target in the past 3 months is 407.60.

Each month's total comprises the sum of three months' worth of ratings.

0QIU Financial Forecast

0QIU Earnings Forecast

Next quarter’s earnings estimate for 0QIU is kr6.01 with a range of kr5.50 to kr6.44. The previous quarter’s EPS was kr4.50. 0QIU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0QIU has Performed in-line its overall industry.

0QIU Sales Forecast

Next quarter’s sales forecast for 0QIU is kr78.66B with a range of kr72.74B to kr82.69B. The previous quarter’s sales results were kr74.98B. 0QIU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0QIU has Performed in-line its overall industry.

0QIU Stock Forecast FAQ

What is GB:0QIU’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 407.60.

What is GB:0QIU’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 31.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 4 hold ratings and 1 sell ratings.

What is Novo Nordisk’s share price target?

The average share price target for Novo Nordisk is 407.60. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr540.00 ,and the lowest forecast is kr290.00. The average share price target represents 31.34% Increase from the current price of kr310.34.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Novo Nordisk?

To buy shares of GB:0QIU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novo Nordisk (0QIU) Share Forecast & Price Target

0QIU Analyst Ratings

0QIU Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

0QIU Analyst Recommendation Trends

0QIU Financial Forecast

0QIU Earnings Forecast

0QIU Sales Forecast

0QIU Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts